Treatments

*October 2022* There was a focus on treating EGFR-positive NSCLC that has progressed after being treated with currently approved EGFR targeted therapies, with several presentations of new drug combinations and new EGFR targeted therapies. Data from the CHRYSALIS-2 trial was presented looking at giving a combination of the new EGFR…

*October 2022* During a Targeted Oncology case-based roundtable discussion, Zofia Piotrowska, MD, MHS, discussed the data from clinical trials supporting mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion mutation. Read more.

*October 2022* RESULTS: As of January 2020, 42 patients were enrolled (N = 36 efficacy-evaluable). Neuropathies were the most common any-grade adverse events reported, with 24 of 42 patients (57%) experiencing at least one event. The pharmacokinetic profile of Teliso-V plus erlotinib was similar to Teliso-V monotherapy. Median PFS for all…

*October 2022* Targeted treatment options for patients with HER2-mutant non–small cell lung cancer (NSCLC) have been slow to reach benchmarks for approval given the limited patient populations harboring this disease characteristic. Three classes of agents have demonstrated efficacy in patients with HER2-mutant disease: tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and…

*October 2022* Drs Benjamin Levy, Neil Morganstein, and Bhuvana Ramkumar discuss challenges of procuring for molecular testing in patients with NSCLC. Watch video here.

*October 2022* Dr. Neil Love and Dr. Pasi Janne discuss the current and future management of EGFR+ NSCLC.  Listen to the audio or read the transcription.

*September 2022* The clinical significance of gene fusions detected by DNA-based next generation sequencing remains unclear as resistance mechanisms to EGFR tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer. By studying EGFR inhibitor-resistant patients treated with a combination of an EGFR inhibitor and a drug targeting the putative…

*October 2022* What happens when your cancer becomes resistant to your course of treatment and progresses? Dr. David Gandara, professor emeritus and co-director of UC Davis Comprehensive Cancer Center’s Center for Experimental Therapeutics, discussed a number of options. The good news is that it turns out there’s a lot that…

*September 2022*  From Dr. Julien Mazieres' presentation at ESMO 2022

*September 2022* Topline data presented at ESMO 2022 showed DZD9008 met its primary end point of objective response rate and had a benign safety profile in non–small cell lung cancer with EGFR exon 20 insertion mutations. DZD9008 (sunvozertinib) in patients with platinum-pretreated non–small cell lung cancer (NSCLC) with EGFR exon…